Lycia Shares Fall Nearly 10% After Hours Following $365.1 Mln IPO Closing
Lycia Therapeutics (LYCA) shares dropped nearly 10% in after-hours trading after closing its $365.1M IPO, selling 20.27M shares at $18 each. Proceeds will fund R&D, including Phase 1 trials for LCA-0061, LCA-0062, and LCA-0321. The company expects funds to last into 2H 2029. LYCA closed Monday at $28.85, down 3.83%.
How this was made
The 30-second read
Why it matters
The immediate price decline reflects concerns over pricing and demand, creating short‑term downside risk but also a possible entry point for risk‑tolerant investors.
Market read
The IPO and price reaction are material for traders focused on biotech listings and short‑term market moves.
What to watch
Potential future data releases from Phase 1 trials and cash runway into 2029 may support a longer‑term upside.
Background
Lycia Therapeutics completed an upsized IPO raising $365.1 M and saw its shares fall nearly 10% after hours, indicating market skepticism.
Ticker impact
Shares fell ~10% in after‑hours trading after the company disclosed it closed its $365.1 M IPO at $18 per share.
likely further pressure as the market digests the IPO pricing and lower-than‑expected demand
A sizable capital raise ($365 M) and a near‑10% after‑hours decline are fresh, material information that typically triggers short‑term sell pressure.
Market effects
Biotech IPO activity may be viewed as a barometer for investor appetite in the sector.
Limited to U.S. markets; Nasdaq biotech listings could see modest ripple effects.
Low; the event is company‑specific without broader macro implications.
Counterpoint
The price drop could present a buying opportunity if the IPO valuation is deemed attractive relative to pipeline potential.
Key entities
- companyLycia Therapeutics, Inc.
Biotech firm that completed a $365.1 M IPO and whose shares fell ~10% after hours.
